Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome.

Hardak E, Avivi I, Berkun L, Raz-Pasteur A, Lavi N, Geffen Y, Yigla M, Oren I.

Infection. 2016 Jan 20. [Epub ahead of print]

PMID:
26792011
2.

Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.

Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, Toledano K, Dagan A, Bishara R, Markovits D, Nahir MA, Braun-Moscovici Y.

Isr Med Assoc J. 2015 Mar;17(3):150-6.

3.

Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease.

Fruchter O, Yigla M, Kramer MR.

Am J Med Sci. 2015 Apr;349(4):338-43. doi: 10.1097/MAJ.0000000000000435.

PMID:
25719977
4.

Evaluation of high-sensitivity serum CRP levels compared to markers of airway inflammation and allergy as predictors of methacholine bronchial hyper-responsiveness in children.

Livnat G, Yoseph RB, Nir V, Hakim F, Yigla M, Bentur L.

Lung. 2015 Feb;193(1):39-45. doi: 10.1007/s00408-014-9658-6. Epub 2014 Oct 21.

PMID:
25331535
5.

D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation.

Fruchter O, Yigla M, Kramer MR.

Am J Med Sci. 2015 Jan;349(1):29-35. doi: 10.1097/MAJ.0000000000000332.

PMID:
25233043
6.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

7.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

8.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
9.

Fulminant pneumonitis: a clue to autoimmune disease.

Naffaa M, Mazor Y, Azzam ZS, Yigla M, Guralnik L, Balbir-Gurman A.

Isr Med Assoc J. 2013 Apr;15(4):195-7. No abstract available.

10.

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*.

Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Erratum in: Ann Intern Med. 2014 May 6;160(9):658.

PMID:
23648946
11.

Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection.

Hardak E, Neuberger A, Yigla M, Berger G, Finkelstein R, Sprecher H, Oren I.

Respirology. 2012 May;17(4):681-6. doi: 10.1111/j.1440-1843.2012.02158.x.

PMID:
22390188
12.

The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.

Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM, Avivi I.

Acta Haematol. 2012;127(2):110-4. doi: 10.1159/000334113. Epub 2011 Dec 16.

PMID:
22178955
13.

Clinical spectrum and outcome of Nocardia infection: experience of 15-year period from a single tertiary medical center.

Hardak E, Yigla M, Berger G, Sprecher H, Oren I.

Am J Med Sci. 2012 Apr;343(4):286-90. doi: 10.1097/MAJ.0b013e31822cb5dc.

PMID:
21825961
14.

Characterization of pulmonary venous hypertension patients with reactive pulmonary hypertension as compared to proportional pulmonary hypertension.

Berger G, Hardak E, Obaid W, Shaham B, Carasso S, Kerner A, Yigla M, Azzam ZS.

Respiration. 2012;83(6):494-8. doi: 10.1159/000329446. Epub 2011 Aug 4.

PMID:
21821999
15.

Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature review.

Toledano K, Guralnik L, Lorber A, Ofer A, Yigla M, Rozin A, Markovits D, Braun-Moscovici Y, Balbir-Gurman A.

Semin Arthritis Rheum. 2011 Dec;41(3):461-70. doi: 10.1016/j.semarthrit.2011.06.001. Epub 2011 Jul 30. Review.

PMID:
21803399
16.

Preliminary prospective explanatory observation on the impact of 3-month steroid therapy on the objective measures of sleep-disordered breathing.

Berger G, Hardak E, Shaham B, Avitan E, Yigla M.

Sleep Breath. 2012 Jun;16(2):549-53. doi: 10.1007/s11325-011-0541-x. Epub 2011 Jul 14.

PMID:
21755279
17.

Polymerase chain reaction-based detection of Pneumocystis jirovecii in bronchoalveolar lavage fluid for the diagnosis of pneumocystis pneumonia.

Oren I, Hardak E, Finkelstein R, Yigla M, Sprecher H.

Am J Med Sci. 2011 Sep;342(3):182-5. doi: 10.1097/MAJ.0b013e318210ff42.

PMID:
21642823
18.

Idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: can we be certain?

Berger G, Azzam ZS, Hardak E, Tavor Y, Yigla M.

Isr Med Assoc J. 2011 Feb;13(2):106-10. Review.

19.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

20.

Obstructive uropathy caused by retroperitoneal fibrosis presents as a late manifestation of sarcoidosis.

Gil A, Ofer Y, Yigla M, Goralnik L, Meretyk S, Assady S.

Ren Fail. 2010;32(9):1118-20. doi: 10.3109/0886022X.2010.510612.

PMID:
20863219
Items per page

Supplemental Content

Loading ...
Write to the Help Desk